More on PPIs and Cdiff risk

>
By  |  February 9, 2012 | 

Another retrospective analysis of patients on acid suppression (H2-PPIs-both) found they had 2.5 times the risk of complications, and almost 5 times the risk of death with Cdiff, compared to those not on these medications (abstract). As such, the FDA has now issued a MedSafety warning on the risk, and advocating using the lowest dose for the shortest time possible (FDA site)

Share This Post

Leave A Comment

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

About the Author: Danielle Scheurer

Danielle Scheurer, MD, MSCR, SFHM is a clinical hospitalist and the Chief Quality Officer at the Medical University of South Carolina in Charleston, South Carolina, where she also serves as Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She is also the President of SHM's Board of Directors and previously served as Physician Editor of The Hospitalist, SHM's monthly newsmagazine.

Categories

Related Posts

November 8, 2019 |  0
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
June 29, 2013 |  0
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
June 22, 2013 |  0
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
Go to Top